12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD

被引：0
|
作者：
Ferguson, G. T. [1 ]
Rabe, K. F. [2 ,3 ]
Bourne, E. [4 ]
Ballal, S. [4 ]
DeAngelis, K.
Aurivillius, M. [5 ]
Reisner, C. [5 ]
Dorinsky, P. [4 ]
机构：
[1] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[2] Lungenclin Grosshansdorf GmbH, Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany
[3] Deutsch Zentrum Lungenforsch Dzl, Airway Res Ctr North Arcn, Giessen, Germany
[4] Pearl Astrazeneca, Wedel, Germany
[5] Astrazeneca, Wedel, Germany
来源：
PNEUMOLOGIE | 2020年 / 74卷
关键词：
D O I：
10.1055/s-0039-3403158
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P294
引用
收藏
页码：S43 / S44
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
    Chen Wang
    Ting Yang
    Jian Kang
    Rongchang Chen
    Li Zhao
    Huijie He
    Pryseley N. Assam
    Rong Su
    Eric Bourne
    Shaila Ballal
    Kiernan DeAngelis
    Paul Dorinsky
    Advances in Therapy, 2020, 37 : 1591 - 1607
  • [42] Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
    Wang, Chen
    Yang, Ting
    Kang, Jian
    Chen, Rongchang
    Zhao, Li
    He, Huijie
    Assam, Pryseley N.
    Su, Rong
    Bourne, Eric
    Ballal, Shaila
    DeAngelis, Kiernan
    Dorinsky, Paul
    ADVANCES IN THERAPY, 2020, 37 (04) : 1591 - 1607
  • [43] Efficacy, Safety And Dose Response Of Glycopyrrolate Metered Dose Inhaler (gp Mdi) Delivered Using Co-Suspension™ Delivery Technology In Patients With Intermittent Or Mild-To-Moderate Persistent Asthma
    Kerwin, E. M.
    Wachtel, A.
    Sher, L.
    Nyberg, J.
    Darken, P.
    Orevillo, C.
    Dorinsky, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [44] Cardiovascular Safety Profile Of A Novel Lama/laba Co-Suspension Technology Fixed-Dose Combination Of Glycopyrrolate/formoterol Delivered By Metered Dose Inhaler In Patients With COPD: 24-Hour Holter Monitoring Study
    Martinez, F. J.
    Fabbri, L. M.
    Rennard, S. I.
    Sethi, S.
    Gottschlich, G.
    Arora, S.
    Darken, P.
    Orevillo, C.
    Siddiqui, S.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [45] Benefit of FDC budesonide (BUD) and formoterol fumarate (FF) FDC delivered by a novel MDI co-suspension technology (BFF MDI), in patients (pts) with moderate-to-severe COPD
    Kerwin, Edward
    Siler, Thomas
    Arora, Samir
    Darken, Patrick
    Orevillo, Chad
    St Rose, Earl
    Reisner, Colin
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [46] Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial
    Rabe, Klaus F.
    Martinez, Fernando J.
    Singh, Dave
    Trivedi, Roopa
    Jenkins, Martin
    Darken, Patrick
    Aurivillius, Magnus
    Dorinsky, Paul
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2021, 15
  • [47] KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD
    Ferguson, Gary T.
    Rabe, Klaus F.
    Martinez, Fernando J.
    Fabbri, Leonardo M.
    Wang, Chen
    Ichinose, Masakazu
    Bourne, Eric
    Ballal, Shaila
    Deangelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [48] Results, Table, and Figure in: Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD (vol 151, pg 340, 2017)
    Martinez, F. J.
    CHEST, 2017, 151 (06) : 1410 - 1410
  • [49] Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults
    Maes, Andrea
    DePetrillo, Paolo
    Siddiqui, Shahid
    Reisner, Colin
    Dorinsky, Paul
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (02): : 223 - 233
  • [50] 24-Hour Lung Function Following The Novel Lama/laba Co-Suspension Technology Of Glycopyrrolate/formoterol Fixed-Dose Combination Mdi, In Patients With Moderate-To-Very-Severe COPD
    Arora, S.
    Delacruz, L.
    Feldman, G.
    Pudi, K.
    Siddiqui, S.
    Orevillo, C.
    Maes, A.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
12345